Literature DB >> 30771084

LATS2 Inhibits Malignant Behaviors of Glioma Cells via Inactivating YAP.

Yi Shi1,2,3, Decheng Geng1,2,3, Yu Zhang1,2,3, Min Zhao1,2,3, Yan Wang1,2, Yang Jiang1,2,3, Rutong Yu4,5, Xiuping Zhou6,7.   

Abstract

We previously reported that LATS2, the upstream serine/threonine kinase of Yes-associated protein (YAP), is downregulated in gliomas and exhibits negative correlation with the prognosis of glioma patients. In this work, we aimed to explore the role and mechanism of large tumor suppressor kinase (LATS2) in the progression of malignant gliomas. We found that over-expression of LATS2 inhibited glioma cell proliferation and migration/invasion, while LATS2 downregulation promoted them. Mechanistically, LATS2 promoted the phosphorylation of YAP without affecting YAP mRNA expression. Inconsistent with some previous reports, both YAPWT and YAP5SA did not affect the level of LATS2, suggesting that LATS2 did not form a feedback loop with YAP in gliomas. Furthermore, mammalian Ste20-like kinases (MST1) over-expression did not affect the phosphorylation of YAP, suggesting that MST1 may not be the essential upstream serine/threonine kinase of Hippo/YAP pathway in gliomas. Together, LATS2 inhibits glioma cell proliferation and migration/invasion by inactivating YAP.

Entities:  

Keywords:  Glioma; LATS2; Migration/invasion; Proliferation; YAP

Mesh:

Substances:

Year:  2019        PMID: 30771084     DOI: 10.1007/s12031-019-1262-z

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  41 in total

1.  High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  R Stupp; J-C Tonn; M Brada; G Pentheroudakis
Journal:  Ann Oncol       Date:  2010-05       Impact factor: 32.976

Review 2.  LATS tumor suppressor: a new governor of cellular homeostasis.

Authors:  Stacy Visser; Xiaolong Yang
Journal:  Cell Cycle       Date:  2010-10-20       Impact factor: 4.534

Review 3.  Malignant gliomas in adults.

Authors:  Patrick Y Wen; Santosh Kesari
Journal:  N Engl J Med       Date:  2008-07-31       Impact factor: 91.245

4.  YAP inhibits squamous transdifferentiation of Lkb1-deficient lung adenocarcinoma through ZEB2-dependent DNp63 repression.

Authors:  Yijun Gao; Wenjing Zhang; Xiangkun Han; Fuming Li; Xujun Wang; Rui Wang; Zhaoyuan Fang; Xinyuan Tong; Shun Yao; Fei Li; Yan Feng; Yihua Sun; Yingyong Hou; Zhongzhou Yang; Kunliang Guan; Haiquan Chen; Lei Zhang; Hongbin Ji
Journal:  Nat Commun       Date:  2014-08-13       Impact factor: 14.919

5.  Mst1 regulates glioma cell proliferation via the AKT/mTOR signaling pathway.

Authors:  Yuewen Chao; Yan Wang; Xuejiao Liu; Peng Ma; Yi Shi; Jian Gao; Qiong Shi; Jinxia Hu; Rutong Yu; Xiuping Zhou
Journal:  J Neurooncol       Date:  2014-11-06       Impact factor: 4.130

6.  Molecular Alterations and Expression Dynamics of LATS1 and LATS2 Genes in Non-Small-Cell Lung Carcinoma.

Authors:  Showkat A Malik; Mosin S Khan; Majeed Dar; Mahboob Ul Hussain; Mohammad A Shah; Sheikh M Shafi; Syed Mudassar
Journal:  Pathol Oncol Res       Date:  2017-04-22       Impact factor: 3.201

7.  Expression and significance of Hippo/YAP signaling in glioma progression.

Authors:  Hao Zhang; Decheng Geng; Jian Gao; Yanhua Qi; Yi Shi; Yan Wang; Yang Jiang; Yu Zhang; Jiale Fu; Yu Dong; Shangfeng Gao; Rutong Yu; Xiuping Zhou
Journal:  Tumour Biol       Date:  2016-10-07

Review 8.  The NDR/LATS protein kinases in immunology and cancer biology.

Authors:  Ahmad A D Sharif; Alexander Hergovich
Journal:  Semin Cancer Biol       Date:  2017-06-01       Impact factor: 15.707

9.  A YAP/TAZ-induced feedback mechanism regulates Hippo pathway homeostasis.

Authors:  Toshiro Moroishi; Hyun Woo Park; Baodong Qin; Qian Chen; Zhipeng Meng; Steven W Plouffe; Koji Taniguchi; Fa-Xing Yu; Michael Karin; Duojia Pan; Kun-Liang Guan
Journal:  Genes Dev       Date:  2015-06-15       Impact factor: 11.361

Review 10.  Upstairs, downstairs: spatial regulation of Hippo signalling.

Authors:  Alexander Fulford; Nicolas Tapon; Paulo S Ribeiro
Journal:  Curr Opin Cell Biol       Date:  2017-11-17       Impact factor: 8.382

View more
  7 in total

1.  MiR-15b-5b Regulates the Proliferation of Prostate Cancer PC-3 Cells via Targeting LATS2.

Authors:  Zhi-Jie Liu; Shi-Hui Liu; Jun-Ru Li; Xiao-Chuan Bie; Yang Zhou
Journal:  Cancer Manag Res       Date:  2020-10-28       Impact factor: 3.989

2.  Use of signals of positive and negative selection to distinguish cancer genes and passenger genes.

Authors:  László Bányai; Maria Trexler; Krisztina Kerekes; Orsolya Csuka; László Patthy
Journal:  Elife       Date:  2021-01-11       Impact factor: 8.140

3.  CircRNA_100395 Carried by Exosomes From Adipose-Derived Mesenchymal Stem Cells Inhibits the Malignant Transformation of Non-Small Cell Lung Carcinoma Through the miR-141-3p-LATS2 Axis.

Authors:  Chong Zhang; Jinlin Cao; Wang Lv; Haibo Mou
Journal:  Front Cell Dev Biol       Date:  2021-03-25

4.  Analysis of the expression and prognostic value of MT1-MMP, β1-integrin and YAP1 in glioma.

Authors:  Yangyang Zhai; Wei Sang; Liping Su; Yusheng Shen; Yanran Hu; Wei Zhang
Journal:  Open Med (Wars)       Date:  2022-03-09

5.  Identifying LATS2 as a prognostic biomarker relevant to immune infiltrates in human esophageal squamous cell carcinoma.

Authors:  Minqi Zhu; Guoran Liao; Yuxuan Wang; Junxian Mo; Dunbo Yi; Yuhong Zhang; Lei Xian
Journal:  Front Genet       Date:  2022-09-02       Impact factor: 4.772

6.  Hypermethylation of LATS2 Promoter and Its Prognostic Value in IDH-Mutated Low-Grade Gliomas.

Authors:  Yuan Gu; Yu Wang; Yebin Wang; Jiaqian Luo; Xin Wang; Mingyue Ma; Wei Hua; Ying Liu; Fa-Xing Yu
Journal:  Front Cell Dev Biol       Date:  2020-10-22

7.  Downregulation of microRNA-224-3p Hampers Retinoblastoma Progression via Activation of the Hippo-YAP Signaling Pathway by Increasing LATS2.

Authors:  Lili Song; Yanxia Huang; Xinli Zhang; Shaoping Han; Min Hou; Hongxia Li
Journal:  Invest Ophthalmol Vis Sci       Date:  2020-03-09       Impact factor: 4.799

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.